One for All and All for One: New Insights into Enhancers Driving MYC Dysregulation.

IF 11.5 Q1 HEMATOLOGY

Blood Cancer Discovery Pub Date : 2025-05-05 DOI:10.1158/2643-3230.BCD-25-0075

Roger Mulet-Lazaro, Ruud Delwel

引用次数: 0

Abstract

The role of the proto-oncogene MYC as a driver of lymphoma has been known since the 1980s, but the mechanisms underlying its dysregulation are not completely understood. In this issue of Blood Cancer Discovery, Iyer and colleagues employ a CRISPR interference screen targeted at open chromatin regions to unveil enhancers critical for MYC overexpression in lymphoma, including a novel regulatory element in the MYC locus that controls germinal center reentry and is recurrently amplified in diffuse large B-cell lymphomas (germinal center B-cell diffuse large B-cell lymphoma). See related article by Iyer et al., p. 233.

查看原文本刊更多论文

我为人人，人人为我：对MYC失调增强因子的新见解。

自20世纪80年代以来，原癌基因MYC作为淋巴瘤驱动因素的作用已经为人所知，但其失调的机制尚不完全清楚。在这一期的《血癌发现》中，Iyer及其同事采用了一种靶向开放染色质区域的CRISPR干扰筛选，揭示了淋巴瘤中MYC过表达的关键增强子，包括MYC基因座上控制生发中心再入的一个新的调控元件，该元件在弥漫性大b细胞淋巴瘤（生发中心b细胞弥漫性大b细胞淋巴瘤）中反复扩增。参见相关文章Iyer等人，第233页。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cancer Discovery Multiple-

CiteScore

12.70

自引率

1.80%

发文量

139

期刊介绍： The journal Blood Cancer Discovery publishes high-quality Research Articles and Briefs that focus on major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. The topics covered include molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution. These subjects are investigated in both animal disease models and high-dimensional clinical data landscapes. The journal also welcomes submissions on new pharmacological, biological, and living cell therapies, as well as new diagnostic tools. They are interested in prognostic, diagnostic, and pharmacodynamic biomarkers, and computational and machine learning approaches to personalized medicine. The scope of submissions ranges from preclinical proof of concept to clinical trials and real-world evidence. Blood Cancer Discovery serves as a forum for diverse ideas that shape future research directions in hematooncology. In addition to Research Articles and Briefs, the journal also publishes Reviews, Perspectives, and Commentaries on topics of broad interest in the field.